Allosteric binders of ACE2 are promising anti-SARS-CoV-2 agents
The COVID-19 pandemic has had enormous health, economic, and social consequences. Vaccines have been successful in reducing rates of infection and hospitalization, but there is still a need for an acute treatment for the disease. We investigate whether compounds that bind the human ACE2 protein can interrupt SARS-CoV-2 replication without damaging ACE2’s natural enzymatic function. Initial compounds were screened for binding to ACE2 but little interruption of ACE2 enzymatic activity. This set of compounds was extended by application of quantitative structure-activity analysis, which resulted in 512 virtual hits for further confirmatory screening. A subsequent SARS-CoV-2 replication assay revealed that five of these compounds inhibit SARS-CoV-2 replication in human cells. Further effort is required to completely determine the antiviral mechanism of these compounds, but they serve as a strong starting point for both development of acute treatments for COVID-19 and research into the mechanism of infection.
Abstract Figure:.
| Errataetall: |
UpdateIn: ACS Pharmacol Transl Sci. 2022 Jun 22;5(7):468-478. - PMID 35821746 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2022) vom: 16. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hochuli, Joshua E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 20.07.2022 published: Electronic UpdateIn: ACS Pharmacol Transl Sci. 2022 Jun 22;5(7):468-478. - PMID 35821746 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2022.03.15.484484 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338440186 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338440186 | ||
| 003 | DE-627 | ||
| 005 | 20231226000659.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.03.15.484484 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1128.xml |
| 035 | |a (DE-627)NLM338440186 | ||
| 035 | |a (NLM)35313579 | ||
| 035 | |a (PII)2022.03.15.484484 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hochuli, Joshua E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Allosteric binders of ACE2 are promising anti-SARS-CoV-2 agents |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.07.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: ACS Pharmacol Transl Sci. 2022 Jun 22;5(7):468-478. - PMID 35821746 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The COVID-19 pandemic has had enormous health, economic, and social consequences. Vaccines have been successful in reducing rates of infection and hospitalization, but there is still a need for an acute treatment for the disease. We investigate whether compounds that bind the human ACE2 protein can interrupt SARS-CoV-2 replication without damaging ACE2’s natural enzymatic function. Initial compounds were screened for binding to ACE2 but little interruption of ACE2 enzymatic activity. This set of compounds was extended by application of quantitative structure-activity analysis, which resulted in 512 virtual hits for further confirmatory screening. A subsequent SARS-CoV-2 replication assay revealed that five of these compounds inhibit SARS-CoV-2 replication in human cells. Further effort is required to completely determine the antiviral mechanism of these compounds, but they serve as a strong starting point for both development of acute treatments for COVID-19 and research into the mechanism of infection | ||
| 520 | |a Abstract Figure: | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Jain, Sankalp |e verfasserin |4 aut | |
| 700 | 1 | |a Melo-Filho, Cleber |e verfasserin |4 aut | |
| 700 | 1 | |a Sessions, Zoe L |e verfasserin |4 aut | |
| 700 | 1 | |a Bobrowski, Tesia |e verfasserin |4 aut | |
| 700 | 1 | |a Choe, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Johnny |e verfasserin |4 aut | |
| 700 | 1 | |a Eastman, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Talley, Daniel C |e verfasserin |4 aut | |
| 700 | 1 | |a Rai, Ganesha |e verfasserin |4 aut | |
| 700 | 1 | |a Simeonov, Anton |e verfasserin |4 aut | |
| 700 | 1 | |a Tropsha, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Muratov, Eugene N |e verfasserin |4 aut | |
| 700 | 1 | |a Baljinnyam, Bolormaa |e verfasserin |4 aut | |
| 700 | 1 | |a Zakharov, Alexey V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2022) vom: 16. März |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2022 |g day:16 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.03.15.484484 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 16 |c 03 | ||